Baseline demographics and treatment data for the IFN and DAA era
| Characteristic | IFN era (n=2688) | DAA era (n=514) | ||||
| Treated (n=599) % | Untreated (n=2089) | P value | Treated (n=394) % | Untreated (n=120) % | P value | |
| Age (years) | 52.3±10.8 | 55.7±10.7 | <0.001 | 56±8.2 | 57.1±8.9 | 0.3 |
| Male gender (%) | 56.6 | 59.6 | 0.19 | 69.3 | 61.7 | 0.12 |
| Medical comorbidities | ||||||
| Coronary artery disease | 9 | 9.3 | 0.84 | 15.2 | 10 | 0.15 |
| Chronic kidney disease | 9.7 | 12.7 | 0.05 | 26.9 | 20.8 | 0.18 |
| Chronic obstructive pulmonary disease | 2.7 | 2.5 | 0.9 | 5.1 | 5.8 | 0.75 |
| Diabetes mellitus | 19.5 | 19.7 | 0.92 | 38.6 | 32.7 | 0.17 |
| Liver-related comorbidities | ||||||
| Cirrhosis | 59.9 | 64.9 | 0.03 | 85.3 | 83.3 | 0.6 |
| Decompensated cirrhosis | 34.6 | 48.1 | < 0.001 | 76.4 | 73.3 | 0.49 |
| Hepatitis B coinfection | 4.2 | 4.9 | 0.5 | 4.3 | 5 | 0.75 |
| Hepatocellular carcinoma | 12.7 | 20.5 | < 0.001 | 40.4 | 44.5 | 0.42 |
| Psychiatric disorder* | 34.2 | 34.4 | 0.93 | 48.2 | 45.8 | 0.65 |
| Ethnicity (%) | 0.004 | 0.07 | ||||
| Caucasian | 57.6 | 52.2 | 50.9 | 39.5 | ||
| Asian | 16.4 | 13.9 | 13.7 | 13.2 | ||
| African-American | 6% | 6.5 | 3.9 | 8.8 | ||
| Hispanic | 14.9 | 21.6 | 29.9 | 35.1 | ||
| Others | 5 | 5.8 | 1.6 | 3.5 | ||
| HCV genotype (n=490/1227/330/80) | 0.1 | 0.7 | ||||
| 1 | 66.1 | 71.9 | 67.9 | 60 | ||
| 2 | 15.5 | 11.3 | 9.4 | 12.5 | ||
| 3 | 13.9 | 12 | 14.9 | 20 | ||
| 4 | 1.6 | 1.9 | 2.7 | 0 | ||
| 6 | 2.9 | 2.9 | 5.2 | 5 | ||
| Sustained virological response rate | 55 | – | – | 88.8 | – | – |
| Antiviral regimen (DAA era only) | – | – | – | – | – | – |
| Ledipasvir/sofosbuvir | 43.4 | |||||
| Simeprevir/sofosbuvir | 24.6 | |||||
| Sofosbuvir/ribavirin | 16.2 | |||||
| Daclatasvir/sofosbuvir | 5.1 | |||||
| Other regimen | 10.7 | |||||
*Psychiatric disorders include depression, bipolar disorder and schizophrenia.
DAA, direct-acting antiviral; IFN, interferon.